Treating asthma: Is there a place for leukotriene receptor antagonists?

Respiratory Medicine

Volumn 99, Issue 6, 2005, Pages 655-662

  Diamant, Zuzana ^a   van der Molen, Thys ^b,c  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Airway inflammation; Asthma; Leukotriene receptor antagonists

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; NITRIC OXIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DISEASE CONTROL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; PATHOPHYSIOLOGY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; THIRST;

ADRENERGIC BETA-AGONISTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHI; BRONCHIAL HYPERREACTIVITY; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; GUIDELINE ADHERENCE; HUMANS; LEUKOTRIENE ANTAGONISTS; LUNG; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 18244404286     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.01.002     Document Type: Article

References (42)

1. W.W. Busse Inflammation in asthma: The cornerstone of the disease and target of therapy J Allergy Clin Immunol 102 1998 S17-S22
2. L.P. Boulet Physiopathology of airway hyperresponsiveness Curr Allergy Asthma Rep 3 2003 166-171
3. P.K. Jeffery Remodeling in asthma and chronic obstructive lung disease Am J Respir Crit Care Med 164 2001 S28-S38
4. B.E. McParland P.T. Macklem P.D. Pare Airway wall remodeling: Friend or foe? J Appl Physiol 95 2003 426-434
5. Global initiative for asthma: Global strategy for asthma management and prevention. NHBLI/WHO workshop, NIH Publication; 1998, 2002.
6. British Thoracic Society guidelines for asthma Thorax 58 Suppl I 2003 i1-i94
7. J.G. Teeter E.R. Bleecker Relationship between airway obstruction and respiratory symptoms in adult asthmatics Chest 113 1998 272-277
8. J.K. Sont L.N. Willems E.H. Bel et al. Clinical control and histopathological outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL study group Am J Respir Crit Care Med 159 1999 1043-1051
9. R.H. Green C.E. Brightling S. McKenna et al. Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial Lancet 360 2002 1715-1721
10. L. Bjermer History and future perspectives of treating asthma as a systemic and small airways disease Respir Med 95 2001 703-719
11. C. Ward M. Pais R. Bish D. Reid B. Feltis D. Johns E.H. Walters Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma Thorax 57 2002 309-316
12. S.A. Kharitonov P.J. Barnes Nitric oxide in exhaled air is a new marker of airway inflammation Monaldi Arch Chest Dis 51 1996 533-537
13. D.B. Allen L. Bielory H. Derendorf R. Dluhy G.L. Colice S.J. Szefler Inhaled corticosteroids: Past lessons and future issues J Allergy Clin Immunol 112 2003 S1-40
14. R. Louis L.C.K. Lau A.O. Bron A.C. Roldaan M. Radermecker R. Djukanovic The relationship between airways inflammation and asthma severity Am J Resp Crit Care Med 161 2000 9-16
15. R. Dworski G.A. Fitzgerald J.A. Oates et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma Am J Respir Crit Care Med 149 1994 953-959
16. J.M. FitzGerald A. Becker M.R. Sears S. Mink K. Chung J. Lee Canadian asthma exacerbation study group. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations Thorax 59 2004 550-556
17. T.W. Harrison J. Oborne S. Newton A.E. Tattersfield Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: A randomised controlled trial Lancet 363 2004 271-275
18. R.A. Pauwels C-G. Löfdahl D.S. Postma A.E. Tattersfield P. O'Byrne P.J. Barnes et al. Effect of inhaled formeterol and budesonide on exacerbations of asthma N Engl J Med 337 1997 1405-1411
19. M.J. Vaquerizo P. Casan J. Casatillo M. Perpina J. Sanchis V. Sobradillo et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma Thorax 58 2003 204-210
20. R.F. Lemanske C.A. Sorkness E.A. Mauger S.C. Lazarus H.A. Boushey J.V. Fahy Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol J Am Med Assoc 285 2001 2594-2603
21. P.M. O'Byrne P.J. Barnes R. Rodriquez-Roisin E. Runnerstrom T. Sandstrom K. Svensson Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial Am J Respir Crit Care Med 164 2001 1392-1397
22. E.D. Bateman H.A. Boushey J. Bousquet W.W. Busse T.J. Clark R.A. Pauwels et al. (GOAL Investigaters Group). Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study AM J Respir Crit Care Med 170 8 2004 836-844
23. A. Wallin T. Sandstrom G.D. Cioppa S. Holgate S. Wilson The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics Respir Med 96 2002 1021-1025
24. A. Wallin M. Sue-Chu L. Bjermer et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma J Allergy Clin Immunol 112 2003 72-78
25. W.J. Calhoun K.L. Hinton J.J. Kratzenberg The effect of salmeterol on markers of airway inflammation following segmental allergen challenge Am J Respir Crit Care Med 163 2001 881-886
26. J.A. Roberts P. Bradding K.M. Britten et al. The long-acting beta2-agonist salmeterol xinafoate: Effects on airway inflammation in asthma Eur Respir J 14 1999 275-282
27. Z. Diamant A.P. Sampson Anti-inflammatory mechanisms of leukotriene modulators Clin Exp Allergy 29 1999 1449-1453
28. P.H. Howarth Leukotrienes in rhinitis Am J Respir Crit Care Med 161 2000 s133-s136
29. J. Fauler Ch. Neumann D. Tsikas et al. Enhanced synthesis of cysteinyl leukotrienes in atopic dermatitis Br J Dermatol 128 1993 627-630
30. A.P. Sampson E. Pizzichini H. Bisgaard Effect of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation J Allergy Clin Immunol 111 2003 S49-S61
31. A.M. Wilson L.C. Orr E.J. Sims et al. Antiasthmatic effects of mediator blockade versus topical cotricosteroids in allergic rhinitis and asthma Am J Respir Crit Care Med 162 2000 1297-1301
32. M. Laviolette K. Malmstrom S. Lu et al. Montelukast added to inhaled beclomethasone in treatment of asthma Am J Respir Crit Care Med 160 1999 1862-1868
33. F.E. Simons J.R. Villa B.W. Lee A.M. Teper B. Lyttle G. Aristizabal et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study J Pediatr 138 2001 694-698
34. D.B. Price D. Hernandez P. Magyar et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma Thorax 58 2003 211-216
35. D.B. Price M.Y. Rouleau C.P. Fletcher et al. Use of montelukast in tapering inhaled corticosteroid therapy: An open-label 48-week trial Curr Ther Res 62 2001 743-755
36. D.S. Robinson D. Campbell P.J. Barnes Addition of leukotriene antagonists to therapy in chronic persistent asthma: A randomised double-blind placebo-controlled trial Lancet 357 2001 2001-2011
37. J.E. Fish E. Israel J.J. Murray et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy Chest 120 2001 423-430
38. H.S. Nelson W.W. Busse E. Kerwin et al. Fluticasone propionate/ salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast J Allergy Clin Immunol 106 2000 1088-1095
39. I.D. Pavord editor Leukotriene antagonists and symptom control in chronic persistent asthma. Editorial Lancet 357 2001 1991-1992
40. A.M. Wilson O.J. Dempsey E.J. Sims B.J. Lipworth Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids Chest 119 2001 1021-1026
41. L. Bjermer H. Bisgaard J. Bousquet et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: One year, double blind, randomised, comparative trial Thorax 327 2003 891-895
42. J.P. Kemp Recent advances in the management of asthma using leukotriene modifiers Am J Respir Med 2 2003 139-156